Edgewise Therapeutics, Inc.
EWTXNASDAQHealthcare● Active
$34.84
$-0.75(-2.11%)
Market Cap$3.7B
P/E Ratio—
52W High$40.765
52W Low$12.15
Edgewise Therapeutics, Inc. (EWTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EWTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.46
Est. -$0.50 · +8.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
EWTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.50 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.50 | -$0.46 | +8.0% | — | — | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.43 | -$0.47 | -9.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.40 | -$0.39 | +2.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.42 | -$0.34 | +19.1% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.45 | -$0.43 | +4.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.39 | -$0.42 | -7.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.37 | -$0.36 | +2.7% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.46
EPS Est.
-$0.50
EPS Surpr.
+8.0%
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.47
EPS Est.
-$0.43
EPS Surpr.
-9.3%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.40
EPS Surpr.
+2.5%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.42
EPS Surpr.
+19.1%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.43
EPS Est.
-$0.45
EPS Surpr.
+4.4%
Revenue
—
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.39
EPS Surpr.
-7.7%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.36
EPS Est.
-$0.37
EPS Surpr.
+2.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.58 | $-0.58 | $-0.58 | 2 |
| Q3 FY2027 | $-0.02 | $-0.02 | $-0.02 | 2 |
| Q2 FY2027 | $-0.55 | $-0.55 | $-0.55 | 2 |
| Q1 FY2027 | $-0.51 | $-0.51 | $-0.51 | 3 |
| Q4 FY2026 | $-0.51 | $-0.51 | $-0.51 | 3 |
| Q3 FY2026 | $-0.59 | $-0.50 | $-0.46 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +8.0% | $36.99 | $35.58 | -3.81% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -9.3% | $30.12 | $29.66 | -1.53% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +2.5% | $17.37 | $17.09 | -1.61% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +19.1% | $13.52 | $12.95 | -4.22% |
| ▲ Q2 FY2025 | May 8, 2025 | +4.4% | $14.52 | $14.70 | +1.24% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -7.7% | $26.17 | $25.53 | -2.45% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +2.7% | $36.62 | $35.43 | -3.25% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +5.6% | $15.88 | $16.19 | +1.95% |
Q2 FY2026-3.81%
Report Date
May 7, 2026
EPS Beat/Miss
+8.0%
Price Before
$36.99
Price After
$35.58
Q1 FY2026-1.53%
Report Date
Feb 26, 2026
EPS Beat/Miss
-9.3%
Price Before
$30.12
Price After
$29.66
Q4 FY2025-1.61%
Report Date
Nov 6, 2025
EPS Beat/Miss
+2.5%
Price Before
$17.37
Price After
$17.09
Q3 FY2025-4.22%
Report Date
Aug 7, 2025
EPS Beat/Miss
+19.1%
Price Before
$13.52
Price After
$12.95
Q2 FY2025+1.24%
Report Date
May 8, 2025
EPS Beat/Miss
+4.4%
Price Before
$14.52
Price After
$14.70
Q1 FY2025-2.45%
Report Date
Mar 3, 2025
EPS Beat/Miss
-7.7%
Price Before
$26.17
Price After
$25.53
Q4 FY2024-3.25%
Report Date
Nov 7, 2024
EPS Beat/Miss
+2.7%
Price Before
$36.62
Price After
$35.43
Q3 FY2024+1.95%
Report Date
Aug 8, 2024
EPS Beat/Miss
+5.6%
Price Before
$15.88
Price After
$16.19
Avg Beat Reaction-1.62%
Avg Miss Reaction-1.99%
Beat Rate6 / 8 quarters
Largest Move-4.22% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EWTX ends December
Edgewise Therapeutics, Inc. (EWTX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.46 — beating the analyst consensus of $-0.50 by +8.0%. The next EWTX earnings date is expected around September 1, 2026.
Each quarter, investors track EWTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EWTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EWTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EWTX earnings · 5 questionsEdgewise Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. EWTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EWTX historically reports after market close (AMC).
EWTX earnings datewhen is EWTX earningsEWTX next earnings datewhen does EWTX report earningsEWTX earnings calendar
▸ Source: FMP · Edgewise Therapeutics, Inc. SEC filings · US GAAP · Edgewise Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026